Search website

If you cannot find, what you are looking for, try searching for it below or visit our FAQ-page.

Close
News & Events »
Mage Biologics announces first subject dosed in a Phase 1 trial with MB-001, an orally administered antibody for Inflammatory Bowel Disease

Press Release

Mage Biologics announces first subject dosed in a Phase 1 trial with MB-001, an orally administered antibody for Inflammatory Bowel Disease

Newark, DE, USA, 10 June 2024, Mage Biologics (“Mage”) announces it has dosed the firs[...] Read more »
Tillotts Pharma and TVM Capital Life Science Announce Formation of Mage Biologics to Develop Innovative Oral Antibody Therapy for Ulcerative Colitis

Press Release

Tillotts Pharma and TVM Capital Life Science Announce Formation of Mage Biologics to Develop Innovative Oral Antibody Therapy for Ulcerative Colitis

Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis Novel anti[...] Read more »
Tillotts Pharma AG announces the launch of Octasa® 1600 mg Tablets in Canada

Press Release

Tillotts Pharma AG announces the launch of Octasa® 1600 mg Tablets in Canada

RHEINFELDEN, Switzerland, 06.04.2023 - Tillotts Pharma AG (“Tillotts”), part of the Ja[...] Read more »
Tillotts Pharma AG feiert die Eröffnung seiner neu renovierten Büroräume in Rheinfelden, Schweiz

Press Release

Tillotts Pharma AG feiert die Eröffnung seiner neu renovierten Büroräume in Rheinfelden, Schweiz

RHEINFELDEN, Schweiz, 24.03.2023 –Tillotts Pharma AG (Tillotts), Teil der japanischen Ze[...] Read more »
Tillotts Pharma AG announces the launch of Octasa® 800mg Tablets in Canada

Press Release

Tillotts Pharma AG announces the launch of Octasa® 800mg Tablets in Canada

RHEINFELDEN, Switzerland, 20.10.2022 - Tillotts Pharma AG (“Tillotts”), part of the J[...] Read more »
Tillotts Pharma AG opens new affiliate in Italy

Press Release

Tillotts Pharma AG opens new affiliate in Italy

Tillotts Pharma opens Italian establishment as a next important step in the expansion [...] Read more »
1 2 3 8